Trade GeoVax Labs, Inc. - GOVX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0364 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.2018 |
| Open | 2.2418 |
| 1-Year Change | 648.51% |
| Day's Range | 2.1718 - 2.2418 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 2.1918 | -0.0500 | -2.23% | 2.2418 | 2.2418 | 2.1418 |
| Jan 17, 2025 | 2.2118 | -0.0300 | -1.34% | 2.2418 | 2.2718 | 2.1918 |
| Jan 16, 2025 | 2.2318 | 0.0100 | 0.45% | 2.2218 | 2.2818 | 2.1918 |
| Jan 15, 2025 | 2.2318 | 0.1200 | 5.68% | 2.1118 | 2.3018 | 2.1118 |
| Jan 14, 2025 | 2.1018 | -0.0300 | -1.41% | 2.1318 | 2.2118 | 2.0718 |
| Jan 13, 2025 | 2.1018 | -0.0500 | -2.32% | 2.1518 | 2.2418 | 2.0218 |
| Jan 10, 2025 | 2.2118 | -0.0100 | -0.45% | 2.2218 | 2.2618 | 2.1418 |
| Jan 8, 2025 | 2.1818 | -0.1600 | -6.83% | 2.3418 | 2.3418 | 2.1518 |
| Jan 7, 2025 | 2.4018 | -0.1700 | -6.61% | 2.5718 | 2.5918 | 2.3318 |
| Jan 6, 2025 | 2.5818 | -0.0600 | -2.27% | 2.6418 | 2.6918 | 2.5418 |
| Jan 3, 2025 | 2.6218 | 0.1500 | 6.07% | 2.4718 | 2.6218 | 2.4718 |
| Jan 2, 2025 | 2.4618 | -0.0600 | -2.38% | 2.5218 | 2.5218 | 2.3518 |
| Dec 31, 2024 | 2.4518 | 0.0200 | 0.82% | 2.4318 | 2.7418 | 2.4318 |
| Dec 30, 2024 | 2.4218 | 0.0400 | 1.68% | 2.3818 | 2.4518 | 2.2618 |
| Dec 27, 2024 | 2.4218 | 0.0800 | 3.42% | 2.3418 | 2.5118 | 2.3418 |
| Dec 26, 2024 | 2.3318 | 0.0500 | 2.19% | 2.2818 | 2.3618 | 2.2318 |
| Dec 24, 2024 | 2.2518 | 0.1100 | 5.14% | 2.1418 | 2.2718 | 2.1418 |
| Dec 23, 2024 | 2.2018 | -0.1000 | -4.34% | 2.3018 | 2.3018 | 2.1118 |
| Dec 20, 2024 | 2.2818 | 0.0100 | 0.44% | 2.2718 | 2.3618 | 2.1818 |
| Dec 19, 2024 | 2.3018 | 0.0400 | 1.77% | 2.2618 | 2.3718 | 2.2018 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
GeoVax Labs, Inc. Company profile
About Geovax Labs Inc
GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The Company is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Geovax Labs Inc revenues decreased 79% to $386K. Net loss increased from $3M to $18.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $2.4M to $15.6M (expense), General and administrative increase of 63% to $3.6M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 40M auth., 15,699,909 issd. Insiders control approx. 39.31%. IPO: NA. Private Placement: 1997, 4.4M shares @ $1. 9/06, Co. acq. by GeoVax, Inc. & name changed from Dauphin Technology, Inc. 04/10, 1-for-50 reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
1900 Lake Park Drive
Suite 380
SMYRNA
GEORGIA 30080
US
News
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
15:24, 21 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com